Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Mackay Medical College currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are distributed across 2 distinct examiners, which indicates that each pending application is being reviewed by a different person. This spread across 2 examiners helps to ensure that the college's prosecution results are not overly influenced by any single examiner's habits.
The portfolio is also active in 2 distinct art units, which corresponds to the number of pending actions and examiners. This means that each of the 2 pending office actions is being handled by a different technical group within the patent office. Such a distribution requires the college to manage its biotechnology filings across 2 different sets of technical and procedural standards.
The busiest examiner for the college is WEDDINGTON, KEVIN E, who is responsible for 1 pending office action. This 1 action is part of the 2 total pending office actions, showing that the workload is evenly divided. The presence of 2 distinct examiners in 2 distinct art units for 2 actions reflects a decentralized prosecution strategy where each case is being evaluated in its own unique context.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEDDINGTON, KEVIN E | 1 | 75.3% | +9.8% |
| GIAMMONA, FRANCESCA FILIPPA | 1 | 37.3% | +58.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18352651 | BIOCHIP AND METHOD FOR TRACKING POSTOPERATIVE RECURRENCE STATUS OF PATIENT WITH LUNG ADENOCARCINOMA | GIAMMONA, FRANCESCA FILIPPA | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18352651 | BIOCHIP AND METHOD FOR TRACKING POSTOPERATIVE RECURRENCE STATUS OF PATIENT WITH LUNG ADENOCARCINOMA | GIAMMONA, FRANCESCA FILIPPA | 14d |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843652 | METHOD FOR PREVENTING OR TREATING HEARING LOSS | WEDDINGTON, KEVIN E | 1629 | §102 | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18352651 | BIOCHIP AND METHOD FOR TRACKING POSTOPERATIVE RECURRENCE STATUS OF PATIENT WITH LUNG ADENOCARCINOMA | GIAMMONA, FRANCESCA FILIPPA | 1681 | §103§112 | Final Rejection | 14d | Pending | Jul 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMackay Medical College has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kevin E Weddington has the most, with 1 of Mackay Medical College's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
